Dirk Schneider

USPTO Granted Patents = 12 (Patent Applications = 15)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 11.3

ph-index = 5

Forward Citations = 71(Granted Patents)

Company Filing History:

6 out of 378

Bayer Pharma Aktiengesellschaft

patents

5 out of 721

Bayer Intellectual Property Gmbh

patents

1 out of 192

Bayer Schering Pharma Ag

patents

Years Active: 2011-2018

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10130633 - Compounds (2018-11-20),

2. 9187428 - Substituted dicyanopyridines and use thereof (2015-11-17),

3. 8987256 - Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof (2015-03-24),

4. 8987248 - Substituted piperidines as Par-1 antagonists (2015-03-24),

5. 8946215 - Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2015-02-03),

6. 8796305 - Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2014-08-05),

7. 8778964 - Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use (2014-07-15),

8. 8691817 - Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof (2014-04-08),

9. 8217063 - Lactam-substituted dicarboxylic acids and use thereof (2012-07-10),

10. 8119663 - Heteroaryl-substituted piperidines (2012-02-21),

11. 8084481 - Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors (2011-12-27),

12. 7985876 - Substituted dibenzoic acid derivatives and use thereof (2011-07-26),

Title: Dirk Schneider: Innovator in Pharmaceutical Compounds

Introduction

Dirk Schneider is a prominent inventor based in Wuppertal, Germany. He has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work primarily focuses on developing novel compounds for the treatment of various diseases, including cancer and cardiovascular disorders.

Latest Patents

Among his latest patents, Dirk Schneider has developed compounds related to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides. These compounds are designed for use in pharmaceutical compositions aimed at treating or preventing diseases such as cancer. Additionally, he has worked on substituted dicyanopyridines, which are intended for the treatment and prophylaxis of cardiovascular disorders.

Career Highlights

Dirk Schneider has had a notable career, working with leading companies in the pharmaceutical industry. He has been associated with Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH, where he has contributed to various innovative projects and research initiatives.

Collaborations

Throughout his career, Dirk has collaborated with esteemed colleagues, including Frank Wunder and Johannes-Peter Stasch. These collaborations have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Dirk Schneider's innovative work in developing pharmaceutical compounds has made a significant impact on the treatment of serious diseases. His contributions continue to advance the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.